Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature
| Autor: | Katsanos, K. H., Tsianos, V. E., Zois, C. D., Zioga, H., Vagias, I., Zervou, E., Christodoulou, D. K., Tsianos, E. V. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Adolescent Lamivudine/administration & dosage/therapeutic use Greece/epidemiology Hepatitis B/*complications/drug therapy/epidemiology Inflammatory Bowel Diseases/*complications/epidemiology Middle Aged Crohn Disease/complications/epidemiology Ribavirin/administration & dosage/therapeutic use Interferon-alpha/administration & dosage/therapeutic use Colitis Ulcerative/complications/epidemiology Treatment Outcome Phosphonic Acids/administration & dosage/therapeutic use Antiviral Agents/administration & dosage/therapeutic use Hepatitis C/*complications/drug therapy/epidemiology Prevalence Humans Adenine/administration & dosage/analogs & derivatives/therapeutic use Drug Therapy Combination Female Aged Retrospective Studies |
| Popis: | BACKGROUND AND AIMS: There is limited data on IBD patients diagnosed with viral hepatitis B and C. The aim of the study was to assess the prevalence of chronic HBV or HCV infection in IBD patients followed by our centre and to describe and review the course of bowel and liver disease during therapy. METHODS: Single centre retrospective study on 482 consecutive IBD patients. Laboratory investigation for HBV and HCV was performed with routine methods. Treatment protocols for HBV included IFNa and nucleot(s)ide administration and for HCV combined IFNa and ribavirin. RESULTS: We diagnosed 15 patients (15/482, 3.1%) with HBV or HCV. Of these, 11 were HBV (11/482, 2.3%) and 4 were HCV (4/482, 0.8%). Nine of eleven HBV patients received antiviral therapy (8 lamivudine, 1 IFNa). Five lamivudine patients were switched to tenofovir and in another one adefovir dipivoxil were added. Bowel disease was in remission in ten of the eleven HBV patients. One patient was diagnosed with carcinoid tumor. Two HCV patients received IFNa that was well tolerated. One HCV patient denied therapy and one died from hepatocellular cancer. Of the seven patients on azathioprine only one achieved sustained response. Four patients on Infliximab achieved bowel disease remission but experienced biochemical or virological flare. CONCLUSIONS: This study demonstrates that prevalence of HBV and HCV infection in a large IBD cohort from Western Balkans is compared to that of the background population. IBD patients under immunosuppressants may apparently be treated with safety if preventive antiviral treatment is administered. J Crohns Colitis |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|